Latest Regulus Therapeutics Stories
LA JOLLA, Calif., Oct.
- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform - LA JOLLA, Calif., Oct.
-New Preclinical Results Increase Mechanistic Understanding of Targeting miR-103/107 for Metabolic Disorders and miR-21 for Renal Dysfunction in Alport Syndrome Patients- LA JOLLA, Calif.,
CARLSBAD, Calif., Oct. 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
CARLSBAD, Calif., Oct. 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
-Newly Allowed Claims Demonstrate Regulus' Leadership in the microRNA Field- LA JOLLA, Calif., Sept.
-ATHENA to Shed Light on Rare, Life-Threatening Kidney Disease - LA JOLLA, Calif., Sept.
PORTLAND, Oregon, September 9, 2014 /PRNewswire/ -- A new report by Allied Market Research, titled "RNA Therapeutics Market (technology, applications, end user and geography)
Your genes are blueprints for proteins, and molecules called microRNA can help to determine how often these genetic blueprints are manufactured into proteins.
LA JOLLA, Calif., Aug. 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc.
- A trick or prank.